METOZOLV ODT

Compare METOZOLV ODT  to:
Compare
Compare

Generic Name for METOZOLV ODT

Metoclopramide (as HCl) 5mg, 10mg; orally-disintegrating tabs; mint flavored.

Legal Classification:

Rx

Pharmacological Class for METOZOLV ODT

Antidopaminergic.

Manufacturer of METOZOLV ODT

Salix Pharmaceuticals, Inc.

Indications for METOZOLV ODT

To relieve symptoms associated with acute and recurrent diabetic gastroparesis.

Adult dose for METOZOLV ODT

Allow tablet to dissolve on tongue. 10mg 4 times daily 30 minutes before meals and at bedtime for 2–8 weeks. Renal impairment: reduce dose.

Children's dosing for METOZOLV ODT

Not recommended.

Contraindications for METOZOLV ODT

When stimulation of GI motility may be dangerous (eg, obstruction, perforation, or hemorrhage). Pheochromocytoma. Epilepsy. Concomitant drugs which may cause extrapyramidal reactions (eg, antidepressants, antipsychotics, neuroleptics).

Warnings/Precautions for METOZOLV ODT

Discontinue if signs/symptoms of tardive dyskinesia develop; risk increases with duration of treatment and total cumulative dose. Parkinsonism. History of depression. Hypertension. CHF. Arrhythmia. Elderly. Pregnancy (Cat.B). Nursing mothers.

Interactions for METOZOLV ODT

Hypertensive crisis with MAOIs. Additive sedation with alcohol, other CNS depressants. Antagonized by anticholinergics and narcotics. Monitor insulin use; may diminish gastric and accelerate intestinal absorption of drugs or food.

Adverse Reactions for METOZOLV ODT

Headache, nausea, vomiting, fatigue, somnolence, dizziness, extrapyramidal effects, parkinsonism, tardive dyskinesia, neuroleptic malignant syndrome, hypertension.

How is METOZOLV ODT supplied?

Tabs—10 x 10 (blister packs)

Related Disease:

Nausea

Related Resources

Zuplenz oral soluble film approved for nausea and vomiting

July 06, 2010

The FDA has approved Zuplenz (ondansetron oral soluble film, from Strativa) for the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting.

Claris Lifesciences' intravenous medications recalled

June 01, 2010

The FDA has notified healthcare professionals not to use the intravenous medications, metronidazole, ciprofloxacin and ondansetron manufactured by Claris Lifesciences due to contamination.

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

Xifaxan 550mg approved to reduce risk of hepatic encephalopathy

March 25, 2010

The FDA has approved Xifaxan (rifaximin tablets, from Salix Pharmaceuticals) 550mg for the reduction in risk of recurrence of overt hepatic encephalopathy in patients ≥18 years of age with advanced liver disease.

Zentrip medicated strips available for motion sickness

January 29, 2010

Sato Pharmaceutical has made available over-the-counter Zentrip (meclizine HCl quick-dissolving strips) for the prevention and relief of nausea, vomiting, and dizziness associated with motion sickness.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions